Education
About Us
Working with TipRanks
Follow Us
Larimar Therapeutics, Inc. (LRMR)
NASDAQ:LRMR
LRMR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.61 - $11.20
Previous CloseN/A
Volume147.46K
Average Volume (3M)947.61K
Market Cap
$128.70M
Enterprise Value$68.61M
Total Cash (Recent Filing)$106.93M
Total Debt (Recent Filing)$7.61M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
May 08, 2025EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.31
Shares Outstanding64,027,890
10 Day Avg. Volume813,926
30 Day Avg. Volume947,612
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.76
Forecast
1Y Price Target
$18.86Price Target Upside838.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
---
Larimar Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsNomlabofusp has the potential to be the first therapy to address frataxin deficiency, which is the root cause of disease in Friedreich's ataxia.
Financial StabilityLRMR ended 2024 with $183.5M in cash, cash equivalents, and marketable securities, which provides runway into 2Q26.
Regulatory ApprovalThe FDA is open to considering skin frataxin levels as a potential novel surrogate endpoint for Accelerated Approval.
Bears Say
Clinical DelaysThe weakness in shares is likely due to the slight delay in data and the disclosure of a protocol amendment to add antihistamine premedication to mitigate the risk of anaphylaxis.
Market PerformanceShares continue to trade at a significant discount in comparison to the nomlabofusp market opportunity.
Safety ConcernsConsidering the prior data update included two serious adverse events in two patients, discussions with the FDA regarding the adequacy of the safety data set required to support BLA submission are ongoing.
---
Ownership Overview
35.39% Insiders
6.71% Mutual Funds
0.34% Other Institutional Investors
50.91% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LRMR FAQ
What was Larimar Therapeutics, Inc.’s price range in the past 12 months?
Larimar Therapeutics, Inc. lowest stock price was $1.61 and its highest was $11.20 in the past 12 months.
What is Larimar Therapeutics, Inc.’s market cap?
Larimar Therapeutics, Inc.’s market cap is $128.70M.
When is Larimar Therapeutics, Inc.’s upcoming earnings report date?
Larimar Therapeutics, Inc.’s upcoming earnings report date is May 08, 2025 which is in 15 days.
How were Larimar Therapeutics, Inc.’s earnings last quarter?
Larimar Therapeutics, Inc. released its earnings results on Mar 24, 2025. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.317 by -$0.133.
Is Larimar Therapeutics, Inc. overvalued?
According to Wall Street analysts Larimar Therapeutics, Inc.’s price is currently Undervalued.
Does Larimar Therapeutics, Inc. pay dividends?
Larimar Therapeutics, Inc. does not currently pay dividends.
What is Larimar Therapeutics, Inc.’s EPS estimate?
Larimar Therapeutics, Inc.’s EPS estimate is -0.42.
How many shares outstanding does Larimar Therapeutics, Inc. have?
Larimar Therapeutics, Inc. has 64,027,890 shares outstanding.
What happened to Larimar Therapeutics, Inc.’s price movement after its last earnings report?
Larimar Therapeutics, Inc. reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.317. Following the earnings report the stock price went down -10.236%.
Which hedge fund is a major shareholder of Larimar Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LRMR
---
Larimar Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.86 (838.31% Upside)
$18.86 (838.31% Upside)
Blogger Sentiment
Bullish
LRMR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 581.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.21%
12-Months-Change
Fundamentals
Return on Equity
-63.58%
Trailing 12-Months
Asset Growth
109.45%
Trailing 12-Months
Company Description
Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
---
LRMR Stock 12 Month Forecast
Average Price Target
$18.86
▲(838.31% Upside)
Technical Analysis
Nektar Therapeutics
―
Tonix Pharma
―
Aldeyra Therapeutics
―
Kodiak Sciences
―
RAPT Therapeutics
―
Best Analysts Covering LRMR
1 Year
1 Year Success Rate
12/25 ratings generated profit
1 Year Average Return
+13.27%
reiterated a buy rating last month
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 48.00% of your transactions generating a profit, with an average return of +13.27% per trade.
---